

IDS Form PTO/SB/08: Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					
(Use as many sheets as necessary)					
Sheet	1	of	1	Application Number	10/523,020
				Filing Date	February 2, 2005
				First Named Inventor	Atsushi Ozaki
				Art Unit	1646 1614
				Examiner Name	To be Assigned 12
				Attorney Docket Number	5273-95



U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS					
Examiner Initials	Cite No. ¹	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (# known)			

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

FOREIGN PATENT DOCUMENTS					
Examiner Initials	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ Number ⁴ Kind Code ⁵ (# known)			

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹				Translation ⁶
		Reference Cited			
<i>10</i>		L. A. SORBERA ET AL., "Tolvaptan," Drugs of the Future, 2002, Vol. 27, No. 4, pp. 350-357.			
		ALBERTO MARTINEZ-CASTELAO, "OPC-31260 Otsuka," Current Opinion in Cardiovascular, Pulmonary & Renal Investigational Drugs, * 1999, Vol. 1, No. 3, pp 423-432.			
		TOSHIO NISHIKIMI ET AL., "Effect of Long-Term Treatment with Selective Vasopressin V1 and V2 Receptor Antagonist on the Development of Heart Failure in Rats," Journal of Cardiovascular Pharmacology, 1996; Vol. 27, No. 2 pp. 275-282.			
		KEISHI SHIMIZU ET AL., "Effects of Oral OPC-31260, a Vasopressin V ₂ -Receptor Antagonist Administration on Arterial Baroreceptor Reflex in Conscious Intact and Adriamycin-Induced Heart Failure Rats, Naika Hokan, 1993, Vol. 40, No. 1, pp 7-11.			
		LOUISE M. BURRELL ET AL., "Long-Term effects of nonpeptide vasopressin V2 antagonist OPC-31260 in heart failure in the rat, American Journal of Physiology, 1998, Vol. 275, No. 1, pp. H-176-H182.			
<i>10</i>		MAREO NAITOH ET AL., "Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs, American Journal of Physiology, 1994, vol. 267, No. 6, Part 2, pp. H2245-H2254.			

Examiner Signature	<i>R. J. H. S.</i>	Date Considered	2/15/07
--------------------	--------------------	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of


2

Complete if Known

Application Number	10/523,020
Filing Date	February 2, 2005
First Named Inventor	Atsushi Ozaki
Art Unit	1615 (614)
Examiner Name	To-be-Assigned

Attorney Docket Number

5273-95



U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS

Examiner Initials	Cite No. ¹	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US5,258,510	11-02-93	Hiidenori Ogawa	
		US-5,753,677	05-19-98	Hiidenori Ogawa	
		US-5,827,862	10-27-98	Yoshitaka Yamamura	
		US-2002128259A1	9-12-02	Ghazzi et al.	
		US-2003008860A1	1-9-03	Bakker-Arkema et al.	
		US-2004176354A1	9-4-04	Bakker Arkema et al.	

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.


FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
		JP-A-80641	03-22-94	Otsuka Pharmaceutical Co Ltd		X-Abstract
		WO 94/01113	01-20-94	Otsuka Pharmaceutical Co Ltd		
		JP-A-8-157368	06-18-96	Otsuka Pharmaceutical Co Ltd		X-Abstract
		JP-A-10-120592	05-12-98	Otsuka Pharmaceutical Co Ltd		X-Abstract
		JP-A-7-188021	07-25-95	Otsuka Pharmaceutical Co Ltd		X-Abstract
		WO 01/54677	08-02-01	Warner-Lambert Company		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation ⁶
		TARESH TANEJA ET AL., "Current Status of Acute Intravenous Therapy for Chronic Heart Failure Exacerbations," CHF September/October 1999, pp 199-207, 215.	
		LEONARD ARNOLDA ET AL., "Vasopressin and angiotensin II contribute equally to the increased afterload in rabbits with heart failure," Cardiovascular Research 1991; 25: pp 68-72.	
		MIHAI GHEORGHIADE ET AL., "Rationale and study design for a multicenter, randomized, double-blind, placebo-controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure," American Heart Journal, Vol. 145, No. 2, February 2003, pp S51-4.	
		C, SERRADEIL-LE GAL ET AL., "Nonpeptide vasopressin receptor antagonists: development of selective and orally active V _{1a} , V ₂ and V _{1b} receptor ligands," Progress In Brain Research, Vol. 139, 2002, pp 197-210.	
		LOUISE M. BURRELL ET AL., "Vasopressin receptor antagonism - a therapeutic option in heart failure and hypertension," Experimental Physiology, March 2000; 85 Spec; pp 259S-265S.	
		YOSHITAKA YAMAMURA ET AL., "OPC-41061, a Highly Potent Human Vasopressin V ₂ -Receptor Antagonist: Pharmacological profile and Aquaretic Effect by Single and Multiple Oral Dosing in Rats," The Journal of Pharmacology and Experimental Therapeutics, December 1998, Vol. 287, No. 3, pp 860-867.	
		B. MAYINGER ET AL., "Nonpeptide vasopressin antagonists: A new group of hormone blockers entering the scene," Experimental and Clinical Endocrinology & Diabetes, 1999, Vol. 107; pp 157-165.	
		MAREO NAITOH ET AL., "Effects of Chronic AVP2R Blockade in Congestive Heart Failure in Sheep," Vasopressin and Oxytocin, Adv Exp Med Biol. 1998; 449, pp 445-446.	
		CHAGRIYA KITIYAKARA ET AL., "Vasopressin V ₂ -receptor antagonists: panaceas for hyponatremia?," Current Opinion in Nephrology and Hypertension, September 1997, Vol. 6, No. 5, pp 461-467.	
		DING-LI XU ET AL., "Upregulation of Aquaporin-2 Water Channel Expression in Chronic Heart Failure Rat," The American Society for Clinical Investigation, Inc. April 1997, Vol. 99, No. 7, pp 1500-1505.	

Rd J. H. 2/15/07

IDS Form PTO/SB/08: Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					
(Use as many sheets as necessary)					
Sheet	2	of	2	Application Number	10/523,020
				Filing Date	February 2, 2005
				First Named Inventor	Atsushi Ozaki
				Art Unit	481-1614
				Examiner Name	To-be-Assigned
				Attorney Docket Number	5273-95

NON PATENT LITERATURE DOCUMENTS					
		The American Society for Clinical Investigation, Inc. April 1997, Vol. 99, No. 7, pp 1500-1505.			
<i>[Signature]</i>		J. G. VERBALIS, "Vasopressin V ₂ receptor antagonists," Journal of Molecular Endocrinology, 2002, Vol. 29, pp 1-9.			
<i>[Signature]</i>		J. DONALD ALBRIGHT ET AL, "Recent Advances in the Discovery and Development of Vasopressin Antagonists: Peptide and Nonpeptide V _{1a} and V ₂ Receptor Antagonists," Current Pharmaceutical Design, 1997, Vol. 3, pp 615-632.			
<i>[Signature]</i>		JUNKANKIKA 41, 150-154, 1997.			
Partial translation					

Examiner Signature	<i>Randy H. Haga</i>	Date Considered	2/15/07
--------------------	----------------------	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

912449_1.DOC

IDS Form PTO/SB/08: Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APR 14 2006	
(Use as many sheets as necessary)					
Sheet	1	of	1	Application Number	10/523,020
				Filing Date	February 2, 2005
				First Named Inventor	Atsushi OZAKI
				Art Unit	1615-1614
				Examiner Name	Not Yet Assigned T2 Henley
				Attorney Docket Number	05273.0095

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS


Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

FOREIGN PATENT DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
	JP 11 021241 A		01-26-1999	Otsuka Pharmaceuticals		Abstract

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation
		GHEORGHIADE MIHAI et al., "Chronic effects of vasopressin receptor blockade with tolvaptan in congestive heart failure: A randomized double-blind trial," Circulation, vol. 102, no. 18Supplement, Oct. 31, 2000, pp. II.592	
		Patent Abstracts of Japan, vol. 1999, no. 04, Apr. 30, 1999 & JP 11 021241 A, Otsuka Pharmaceuticals Co., Ltd., Jan. 26, 1999, Abstract	
		Supplementary European Search Report, issued in EP 04 71 3672, February 3, 2006.	

Examiner Signature		Date Considered	2/15/07
-----------------------	---	--------------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<p>IDS Form PTO/SB/08: Substitute for form 1449A/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(Use as many sheets as necessary)</p>				Complete if Known	
				<i>Application Number</i>	10/523,020
				<i>Filing Date</i>	February 2, 2005
				<i>First Named Inventor</i>	Atsushi OZAKI
				<i>Art Unit</i>	1615 1614
				<i>Examiner Name</i>	Not Yet Assigned R. Henley
				<i>Attorney Docket Number</i>	05273.0095

JUL 19 2006

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

She

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENT						
Examiner Initials	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known) JP-A-06-80641	03-22-1994	Otsuka Pharmaceutical	_____	Abstract

NON-PATENT LITERATURE DOCUMENTS

NON-PATENT LITERATURE DOCUMENT			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation ⁸

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.